Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin

Brain Research

Volumn 984, Issue 1-2, 2003, Pages 224-232

  Parain, Karine ^a   Hapdey, Céline ^a   Rousselet, Estelle ^a   Marchand, Véronique ^b   Dumery, Bernard ^b   Hirsch, Etienne C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Altadis   (France)

Author keywords

Cigarette smoke; MPTP; Nicotine; Parkinson's disease; Striatum; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CIGARETTE SMOKE; NEUROPROTECTIVE AGENT; NICOTINE; PLACEBO; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CELL LOSS; CIGARETTE SMOKING; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE ENDING; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA;

EID: 0042155870     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)03195-0     Document Type: Article

References (51)

1. Akaike A., Tamura Y., Yokota T., Shimohama S., Kimura J. Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res. 644:1994;181-187.
2. Baron J.A. Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious. Br. Med. Bull. 52:1996;58-73.
3. Behmand R.A., Harik S.I. Nicotine enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. J. Neurochem. 58:1992;776-779.
4. Campbell K.J., Takada M., Hattori T. Evidence for the retrograde axonal transport of MPP+ in the rat. Neurosci. Lett. 118:1990;151-154.
5. Carr L.A., Rowell P.P. Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by tobacco smoke. Neuropharmacology. 29:1990;311-314.
6. Carr L.A., Basham J.K. Effects of tobacco smoke constituents on MPTP-induced toxicity and monoamine oxidase activity in the mouse brain. Life Sci. 48:1991;1173-1177.
7. Castagnoli K.P., Steyn S.J., Petzer J.P., Van der Schyf C.J., Castagnoli N.J. Neuroprotection in the MPTP Parkinsonian C57BL/6 mouse model by a compound isolated from tobacco. Chem. Res. Toxicol. 14:2001;523-527.
8. Clarke P.B., Hommer D.W., Pert A., Skirboll L.R. Electrophysiological actions of nicotine on substantia nigra single units. Br. J. Pharmacol. 85:1985;827-835.
9. Dajas-Bailador F.A., Lima P.A., Wonnacott S. The alpha7 nicotinic acetylcholine receptor subtype mediates nicotine protection against NMDA excitotoxicity in primary hippocampal cultures through a Ca(2+) dependent mechanism. Neuropharmacology. 39:2000;2799-2807.
10. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain. 122:1999;1421-1436.
11. Fa M., Carcangiu G., Passino N., Ghiglieri V., Gessa G.L., Mereu G. Cigarette smoke inhalation stimulates dopaminergic neurons in rats. Neuroreport. 11:2000;3637-3639.
12. Ferger B., Spratt C., Earl C.D., Teismann P., Oertel W.H., Kuschinsky K. Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo. Naunyn Schmiedebergs Arch. Pharmacol. 358:1998;351-359.
13. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., MacGregor R., Alexoff D., Shea C., Schlyer D., Wolf A.P., Warner D., Zezulkova I., Cilento R. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 379:1996;733-736.
14. Fowler J.S., Volkow N.D., Logan J., Pappas N., King P., MacGregor R., Shea C., Garza V., Gatley S.J. An acute dose of nicotine does not inhibit MAO B in baboon brain in vivo. Life Sci. 63:1998;L19-L23.
15. Fratiglioni L., Wang H.X. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav. Brain Res. 113:2000;117-120.
16. Fung Y.K., Fiske L.A., Lau Y.S. Chronic administration of nicotine fails to alter the MPTP-induced neurotoxicity in mice. Gen. Pharmacol. 22:1991;669-672.
17. Fuxe K., Andersson K., Harfstrand A., Agnati L.F. Increases in dopamine utilization in certain limbic dopamine terminal populations after a short period of intermittent exposure of male rats to cigarette smoke. J. Neural Transm. 67:1986;15-29.
18. Gao Z.G., Cui W.Y., Zhang H.T., Liu C.G. Effects of nicotine on 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced depression of striatal dopamine content and spontaneous locomotor activity in C57 black mice. Pharmacol. Res. 38:1998;101-106.
19. Garrido R., Malecki A., Hennig B., Toborek M. Nicotine attenuates arachidonic acid-induced neurotoxicity in cultured spinal cord neurons. Brain Res. 861:2000;59-68.
20. Grady S.R., Marks M.J., Collins A.C. Desensitization of nicotine-stimulated [3H]dopamine release from mouse striatal synaptosomes. J. Neurochem. 62:1994;1390-1398.
21. Hariharan M., VanNoord T., Greden J.F. A high-performance liquid-chromatographic method for routine simultaneous determination of nicotine and cotinine in plasma. Clin. Chem. 34:1988;724-729.
22. Hauptmann N., Shih J.C. 2-Naphthylamine, a compound found in cigarette smoke, decreases both monoamine oxidase A and B catalytic activity. Life Sci. 68:2001;1231-1241.
23. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science. 224:1984;1451-1453.
24. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature. 311:1984;467-469.
25. Hirsch E., Graybiel A.M., Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature. 334:1988;345-348.
26. Hirsch E.C., Faucheux B.A. Iron metabolism and Parkinson's disease. Mov. Disord. 13:(Suppl. 1):1998;39-45.
27. Janson A.M., Fuxe K., Sundstrom E., Agnati L.F., Goldstein M. Chronic nicotine treatment partly protects against the 1-methyl-4-phenyl-2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse. Acta Physiol. Scand. 132:1988;589-591.
28. Janson A.M., Fuxe K., Goldstein M. Differential effects of acute and chronic nicotine treatment on MPTP-(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse. Clin. Invest. 70:1992;232-238.
29. Janson A.M., Moller A. Chronic nicotine treatment counteracts nigral cell loss induced by a partial mesodiencephalic hemitransection: an analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat. Neuroscience. 57:1993;931-941.
30. Lapin E.P., Maker H.S., Sershen H., Lajtha A. Action of nicotine on accumbens dopamine and attenuation with repeated administration. Eur. J. Pharmacol. 160:1989;53-59.
31. Linert W., Bridge M.H., Huber M., Bjugstad K.B., Grossman S., Arendash G.W. In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson's and Alzheimer's diseases. Biochim. Biophys. Acta. 1454:1999;143-152.
32. Maggio R., Riva M., Vaglini F., Fornai F., Racagni G., Corsini G.U. Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism. J. Neural Transm. 104:1997;1113-1123.
33. Marin P., Maus M., Desagher S., Glowinski J., Premont J. Nicotine protects cultured striatal neurones against N-methyl-D-aspartate receptor-mediated neurotoxicity. Neuroreport. 5:1994;1977-1980.
34. McGehee D.S., Heath M.J., Gelber S., Devay P., Role L.W. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science. 269:1995;1692-1696.
35. Mendez-Alvarez E., Soto-Otero R., Sanchez-Sellero I., Lopez-Rivadulla L.M. Inhibition of brain monoamine oxidase by adducts of 1,2,3,4-tetrahydroisoquinoline with components of cigarette smoke. Life Sci. 60:1997;1719-1727.
36. Norman T.R., Chamberlain K.G., French M.A., Burrows G.D. Platelet monoamine oxidase activity and cigarette smoking. J. Affect. Disord. 4:1982;73-77.
37. Olale F., Gerzanich V., Kuryatov A., Wang F., Lindstrom J. Chronic nicotine exposure differentially affects the function of human alpha3, alpha4, and alpha7 neuronal nicotinic receptor subtypes. J. Pharmacol. Exp Ther. 283:1997;675-683.
38. Oreland L., Fowler C.J., Schalling D. Low platelet monoamine oxidase activity in cigarette smokers. Life Sci. 29:1981;2511-2518.
39. Parain K., Marchand V., Dumery B., Hirsch E. Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice. Brain Res. 890:2001;34-50.
40. Perry T.L., Godin D.V., Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci. Lett. 33:1982;305-310.
41. Perry T.L., Hansen S., Jones K. Exposure to cigarette smoke does not decrease the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neurosci. Lett. 74:1987;217-220.
42. Picciotto M.R., Zoli M., Rimondini R., Lena C., Marubio L.M., Pich E.M., Fuxe K., Changeux J.P. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature. 391:1998;173-177.
43. Rowell P.P. Nanomolar concentrations of nicotine increase the release of [3H]dopamine from rat striatal synaptosomes. Neurosci. Lett. 189:1995;171-175.
44. Salminen O., Seppa T., Gaddnas H., Ahtee L. The effects of acute nicotine on the metabolism of dopamine and the expression of Fos protein in striatal and limbic brain areas of rats during chronic nicotine infusion and its withdrawal. J. Neurosci. 19:1999;8145-8151.
45. Sershen H., Mason M.F., Reith M.E., Hashim A., Lajtha A. Effect of nicotine and amphetamine on the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. Neuropharmacology. 25:1986;1231-1234.
46. Shahi G.S., Das N.P., Moochhala S.M. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: partial protection against striato-nigral dopamine depletion in C57BL/6J mice by cigarette smoke exposure and by beta-naphthoflavone-pretreatment. Neurosci. Lett. 127:1991;247-250.
47. Turski L., Bressler K., Rettig K.J., Loschmann P.A., Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature. 349:1991;414-418.
48. Yamamoto I., Inoki R., Iwatsubo K. Accumulation of 14C-nicotine in mouse brain after the intraperitoneal injection. Jpn. J. Pharmacol. 17:1967;134-135.
49. Yong V.W., Perry T.L. Monoamine oxidase B, smoking, and Parkinson's disease. J. Neurol. Sci. 72:1986;265-272.
50. Yu H., Matsubayashi H., Amano T., Cai J., Sasa M. Activation by nicotine of striatal neurons receiving excitatory input from the substantia nigra via dopamine release. Brain Res. 872:2000;223-226.
51. Yu P.H., Boulton A.A. Irreversible inhibition of monoamine oxidase by some components of cigarette smoke. Life Sci. 41:1987;675-682.